Latest stories on BHVN
Biohaven presents preclinical data for novel TRAP degrader at ASN Kidney Week
The Fly58 · neutralproduct/pr
Biohaven price target raised to $22 from $19 at RBC Capital
The Fly64 · neutralanalyst
Biohaven price target raised to $48 from $42 at Baird
The Fly64 · neutralanalyst
Biohaven Stock Soars As FDA Accepts Vyglyxia Resubmission - This Plot Is Too Thick For Me
Seeking Alpha64 · neutralproduct/pr
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
Barron's74 · bullishproduct/pr
Baird raises Biohaven Pharma stock price target on NDA acceptance
Investing.com Analyst Ratings64 · neutralanalyst
BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia
Stocktwits News78 · bullishproduct/pr
Biohaven surges as FDA accepts resubmission for Vyglxia for spinocerebellar ataxia
Seeking Alpha74 · bullishproduct/pr
Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting
Investors.com74 · bullishgeneral
Why Biohaven's 36% Surge Might Just Be The Beginning
Investors.com74 · bullishgeneral
Why Is Biohaven Stock (BHVN) Up 34% Today?
TipRanks74 · bullishgeneral
Biohaven shares jump 29% premarket as FDA accepts Vyglxia resubmission
The Fly74 · bullishproduct/pr
Biohaven Shares Rise as FDA Accepts Vyglxia Resubmission
MarketWatch64 · neutralproduct/pr
Biohaven’s Vyglxia NDA Resubmission Gains FDA Review
TipRanks63 · neutralproduct/pr
Why is Biohaven stock surging today?
Investing.com Markets72 · bullishgeneral
Biohaven stock surges 25% on FDA acceptance of drug filing
Investing.com Markets74 · bullishproduct/pr
Biohaven Ltd. (BHVN) files 8-K
SEC 8-K50 · neutralgeneral
Biohaven Ltd. (BHVN) files 8-K
SEC 8-K53 · neutralgeneral
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Stocktwits News58 · neutralm&a
Biohaven Pharma stock maintained at buy by Canaccord on licensing deal
Investing.com Analyst Ratings63 · neutralanalyst
Raymond James reiterates Strong Buy on Biohaven stock after Japan deal
Investing.com Analyst Ratings64 · neutralanalyst
Biohaven licenses IgG degrader portfolio to Japan’s Ono
Seeking Alpha63 · neutralm&a
Biohaven Strikes Ono Pharma License: $80M Upfront and ~20% Royalties for Phase 3 Graves’ Candidate BHV-1300 in Key Asian Markets
October 8, 2026
MarketChameleon67 · bullishproduct/pr